Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Nurix Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get NRIX alerts

About Hans van Houte

Hans van Houte is recorded as CFO at Nurix Therapeutics, Inc. (NRIX). The newest filing on record that lists Hans van Houte as CFO at Nurix Therapeutics, Inc. (NRIX) is dated March 27, 2026. The proxy statement of Nurix Therapeutics, Inc. reports total compensation of $2,296,503 for Hans van Houte in fiscal 2025, including a base salary of $545,833. Disclosed compensation is on record for 5 fiscal years. Nurix Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Nurix Therapeutics, Inc. includes Arthur T. Sands (CEO and Board Member), Stefani Wolff (COO), Christine Ring (General Counsel) and 7 others.

Affiliation history

Company network

Leadership on record at Nurix Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Nurix Therapeutics, Inc. (NRIX) $545,833 $2,296,503
2024 Nurix Therapeutics, Inc. (NRIX) $498,675 $2,016,482
2023 Nurix Therapeutics, Inc. (NRIX) $482,925 $1,611,987
2022 Nurix Therapeutics, Inc. (NRIX) $465,417 $4,307,781
2021 Nurix Therapeutics, Inc. (NRIX) $413,750 $1,659,957

Recent activity

No call appearances or filed executive changes recorded yet.